Search for: "United States v. General Electric Company" Results 501 - 520 of 679
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
2 Sep 2017, 9:00 am by Michael H Cohen
Class II devices are subject general controls and special controls. [read post]
14 Mar 2016, 2:56 am by Kevin LaCroix
  In Avon State Bank, David Gibson, a man who purported to be the son of a business associate of Ambrose Herdering, a customer of Avon State Bank, sought out the assistance of Herdering in moving the estate of Gibson’s deceased father from the Netherlands to the United States. [read post]
15 Oct 2021, 7:04 am by Cinthia Macie
  Sua sponte, the agency issued a new Business Review Letter in 2020 to withdraw the Division’s 2015 support for the Institute of Electrical and Electronics Engineers’ (IEEE) policy of calculating royalties on the smallest saleable patent practicing unit—a  limitation on the market power of SEP owners. [read post]
11 Jan 2022, 2:41 am by rainey Reitman
The United States already has laws against redlining, where financial companies engage in discriminatory practices such as preventing people of color from getting home loans. [read post]
11 Oct 2010, 9:05 pm
The drywalls in question were imported into the United States from China between 2001 until 2007 due to the shortage of US produced drywall. [read post]
12 Oct 2017, 6:26 am by Miriam Seifter
” Rachel Kovner of the U.S. solicitor general’s office, representing the United States, stressed that point: The rule is a limitation because it restricts where pollutants can be discharged. [read post]
29 Jun 2018, 11:53 am by Edith Roberts
Crown Cork & Seal, in 2010, in which Willett concurred in a decision striking down a statute that shielded a company from successor liability in a tort case. [read post]
25 Jul 2011, 1:07 am by Melina Padron
will be decided this week, this time by the European Patent Office in Human Genome Sciences Inc v Eli Lilly and Company [2010] EWCA Civ 33. [read post]
15 Mar 2008, 7:00 am
India: Gene silencing: (Spicy IP), India: US Patent reform implications for Indian Pharma: (Spicy IP), India: Generic pharmaceutical industry in the spotlight: (International Law Office), India: Supreme Court refuses to stay a Gujarat High Court decision restraining Ranbaxy from airing its controversial ads directed against Paras Pharma's 'Moov' brand: (Spicy IP),India: Patents on ARV drugs could increase costs: (Generic Pharmaceuticals & IP),US: Survey… [read post]